Digital Edition

Ophthalmology Times: May 2023
Volume: 48
Issue: 5

Ophthalmology Times: April 2023
Volume: 48
Issue: 4

Ophthalmology Times: March 2023
Volume: 48
Issue: 3

Ophthalmology Times: February 2023
Volume: 48
Issue: 2

Ophthalmology Times: January 2023
Volume: 48
Issue: 1

Ophthalmology Times: December 2022
Volume: 47
Issue: 12

Ophthalmology Times: November 2022
Volume: 47
Issue: 11

Ophthalmology Times: October 2022
Volume: 47
Issue: 10

Ophthalmology Times: September 2022
Volume: 47
Issue: 9

Ophthalmology Times: August 2022
Volume: 47
Issue: 8

Ophthalmology Times: July 2022
Volume: 47
Issue: 7

Ophthalmology Times: June 2022
Volume: 47
Issue: 6

Ophthalmology Times: May 2022
Volume: 47
Issue: 5

Ophthalmology Times: April 2022
Volume: 47
Issue: 4

Ophthalmology Times: March 2022
Volume: 47
Issue: 3

Ophthalmology Times: February 2022
Volume: 47
Issue: 2

Ophthalmology Times: January 2022
Volume: 47
Issue: 1

Ophthalmology Times: December 2021
Volume: 46
Issue: 20

Ophthalmology Times: November 15, 2021
Volume: 46
Issue: 19

Ophthalmology Times: November 1, 2021
Volume: 46
Issue: 18

Ophthalmology Times: October 15, 2021
Volume: 46
Issue: 17

Ophthalmology Times: October 1, 2021
Volume: 46
Issue: 16

Ophthalmology Times: September 15, 2021
Volume: 46
Issue: 15

Ophthalmology Times: September 1, 2021
Volume: 46
Issue: 14

Ophthalmology Times: August 2021
Volume: 46
Issue: 12

Ophthalmology Times: July 15, 2021
Volume: 46
Issue: 12

Ophthalmology Times: July 1, 2021
Volume: 46
Issue: 11

Ophthalmology Times: June 15, 2021
Volume: 46
Issue: 10

Ophthalmology Times: June 1, 2021
Volume: 46
Issue: 09

Ophthalmology Times: May 2021
Volume: 46
Issue: 8
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Johnson & Johnson to acquire Ollin Biosciences in deal worth up to $3.3 billion
2
Q&A: What the FDA’s class-wide NAION warning on GLP-1s means for eye care
3
Dazodalibep data put Sjögren screening in focus for ophthalmologists
4
Q&A: Caroline R. Baumal, MD, from academic retina to the C-suite and back | Eichenbaum Acorns
5
